Pfizer, Teva reach deal to allow generic Viagra
Fifteen years after Pfizer Inc.’s Viagra changed the sexual equation for older men, the blockbuster impotence drug is set to become available in a less expensive generic form as early as 2017.
Pharmaceutical
Articles
Lilly foe still testing Alzheimer’s theory where others failed
Since 1998, there have been more than 100 attempts to develop an Alzheimer’s treatment, and all have failed. Such a product may generate as much as $5 billion annually for Merck, according to analysts
FDA approves first generic versions of Lilly’s Cymbalta
Cymbalta is Eli Lilly and Co. Inc.'s best-selling drug and posted 2012 sales of $4.7 billion, making it the fifth-highest selling medication in the world. The drug's patent expired Wednesday.
Lilly set to fall off second patent cliff
Eli Lilly and Co. on Wednesday will fall off its second “patent cliff” in as many years as its best-selling drug Cymbalta sees its U.S. patents expire.
Lilly depression drug fails to meet goals in studies
Edivoxetine, a derivative of Lilly's Strattera drug for attention deficit disorder, was in the final of three stages of testing usually required for marketing approval by U.S. regulators.
Lilly pledges up to $1.8B to Pfizer for access to potential blockbuster
Eli Lilly and Co. and Pfizer Inc., which are both suffering through some of the largest patent cliffs in the industry, will split any future costs and profits of an osteoarthritis drug that has stalled in clinical testing.
MILLER: Specialty medications have potential to cut costs
Today’s specialty medications are modern miracles, helping millions of patients with chronic, life-threatening illnesses such as cancer, multiple sclerosis and rheumatoid arthritis.
Bribery scandals sap Lilly’s China growth
Eli Lilly and Co. has been counting on torrid growth in China to help offset losses from patent expirations in other markets, but now slower growth in the Chinese economy and bribery allegations against Lilly and two other drugmakers have hampered Lilly’s growth there.
Investors brace for lean years from Lilly
In a new round of predictions this month, Wall Street analysts indicated they expect Eli Lilly and Co.’s revenue to fall next year and to remain below 2013 levels until 2020.
Financial pressures stretching Lilly
In a series of presentations, Lilly executives stretched themselves in four directions at once to convince investors and stock analysts that the company will bend but not break next year, and then snap back stronger than ever in 2015.
Lilly, other drugmakers itching to find new psoriasis treatment
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
Lilly shares dip after cancer treatment misses goal
Eli Lilly said a potential breast cancer treatment missed its main goal in a late-stage study. However, the drugmaker will seek approval to use the treatment in stomach cancer patients after ramucirumab performed better in a separate study.
Lilly bets quality over quantity will pay off in diabetes battle
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
Carmel pharmaceutical firm eyeing move to Noblesville
A Carmel institutional pharmacy could move its growing drug repackaging operation to Noblesville’s Corporate Campus if city leaders sign off on $225,000 in tax breaks.
Drugmakers turn up marketing efforts in diabetes market
With a half-dozen new products lined up for approval within two years, the fight to win the growing $22 billion U.S. diabetes market is expected to intensify.
China bribery probe leading to tough drug market, CEO says
Drugmakers under investigation for bribery have stopped promoting products in China, and physicians in some hospitals no longer want to meet sales representatives. Eli Lilly is among the drugmakers in China facing allegations.
Indiana board considers 1-year delay of patient tests
Indiana's Medical Licensing Board is considering delaying for one year a proposed new rule that would require physicians to conduct annual toxicology tests on some patients as part of a larger state effort to crack down on prescription drug abuse.
Doctor charged with overprescribing painkillers
Dr. Segun Rasaki, 49, prescribed drugs like hydrocodone and methadone to people who didn’t need them, and submitted fraudulent insurance claims such as duplicate billings, according to court documents.
Lilly lung cancer drug raises patient survival in trial
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
Lilly aims potential Alzheimer’s drug at early patients
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.